Breast cancer is a heterogeneous disease, which is characterized by a number of distinct biological entities associated with specific morphological and immunohistochemical features and clinical behavior.(1) Molecular and gene expression profiling studies have demonstrated that breast cancers comprise a group of tumors of several subtypes, including the luminal subtypes (hormone receptor-positive), the human epidermal growth factor receptor 2 (HER2)-positive, and the basal like subtype.(2) Basal-like breast cancer exhibits molecular characteristics that are predictive of a poor prognosis. In one previous study, intrinsic subtypes were compared with prognostic profiles in patients suffering from basal-like breast cancer, all of whom had a poor 70-gene profile, activated wound response, and high recurrence score.(3) Despite differences in the definition and prevalence of basal-like breast cancer in a variety of studies, the clinical outcomes of patients were generally poor.(4) However, no gene array profiling technique is currently clinically available, and immunohistochemical surrogate profiles for the basal-like profile have not yet been standardized or validated.(5) We utilized triple-negative breast cancers (TNBC) as a surrogate to represent the basal-like category of breast cancers because the immunostaining data were available.
INTRODUCTION
TNBC has become a commonly utilized descriptor for malignancies that estrogen receptor (ER), progesterone receptor (PR), and HER2 are all negative. TNBCs account for 10-17% of all breast carcinomas, depending on the thresholds employed to define ER and PR positivity, as well as the methods for HER2 assessment. (6) It has been well established that TNBC patients feature a relatively aggressive clinical course.(4) However, there have only been a few reports conducted thus far concerning TNBC with brain metastasis. (7) (8) (9) The principal objective of this study was to assess clinical outcomes in TNBC patients with brain metastasis.
METHODS

Patients
We conducted a retrospective analysis using the medical records of patients who had been diagnosed with brain 
Treatment of brain metastasis
Patients with BM were treated as indicated with at least one of the following treatment modalities: whole brain radiotherapy (WBRT), surgical resection, and systemic treatments including chemotherapy and endocrine therapy. Corticosteroid treatment was administered after diagnosis, and continued throughout the ensuing treatment regimen. All patients with brain metastases were treated WBRT. The total dose was 30 Gy, applied in 10 fractions over two weeks. Intrathecal therapy for patients with leptomeningeal disease consisted of lumbar puncture or Ommaya reservoir with methotrexate 10-15 mg twice a week until malignant cells could no longer be detected in the cerebrospinal fluid.
Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)
Immunohistochemical analyses of ER and PR status were conducted using 4-mm sections of paraffin-embedded tissue specimens that were stained with monoclonal antibodies for ER (DAKO Co., Carpinteria, USA) and PR (DAKO Co.). We chose a cut-off level for negative cases of less than 10% positive nuclei with weak staining intensity, which is equal to Allred score 2. The tumor was considered to be HER2-positive if the primary or metastatic tumor was scored 3+ by HER2 IHC (Neo Markers, Fremont, USA), or in the case of IHC 2+ with HER2 gene amplification identified via the FISH method. TNBCs were defined as those that were ER-negative, PR-negative, and HER2-negative. 
Statistical analyses
RESULTS
Patient characteristics
The clinical characteristics of the BM patients and the relationship with receptor status are presented in Table 1 .
Twenty four patients (40.0%) were diagnosed with TNBC.
The median age at diagnosis of BM in the TNBC groups was 49 yr (range, 30-74 yr). Three patients had stage I disease at diagnosis, 9 patients had stage II, 12 patients had stage III at primary presentation. Approximately 88% of patients had T1 or T2 disease, and 70% were lymph node positive. Thirteen patients had histologic grade (HG) 1 or 2 tumors, and the others had HG 3 tumors. The most frequent presenting signs and symptoms of BM were headache, nausea, and vomiting, followed by dizziness, double vision, and unilateral weakness of the extremities.
The brain was the first site of metastasis in 7 patients (29.2%) and was accompanied, in the majority of cases, by other sites of metastatic disease. The most common sites of extracranial metastasis were the lung (60%), bone (50%), liver (45%), and the lymph nodes (45%). In 6 patients (25.0%), a single BM was detected, and in 18 patients multiple parenchymal BM occurred; leptomeningeal carcinomatosis was not observed in any of the TNBC patients.
However, the clinicopathologic parameters did not differ according to the breast cancer subtype ( Table 1) .
Clinical outcome according to breast cancer subtypes
The disease-free survival durations of non-TNBC and TNBC patients were 25.6 months and 17.9 months, respectively (p=0.135). The median time intervals from distant metastasis to BM were 19.5 months and 8.4 months, respectively (p=0.006). The median times from initial diagnoses to BM were 43.7 and 25.5 months, respectively (p=0.027; Figure 1 ). Primary tumor characteristics and the interval duration from initial diagnosis to BM are provided in Table 2 . Histologic grade (p=0.036), ER status (p=0.005), vascular invasion (p=0.007), subtype (p=0.027) were significantly related to the time interval from initial diagnosis to BM. However, only histologic grade was independent prognosis factor (relative risk [RR], 0.039; 95% confidence interval [CI], 1.034-3.668; p=0.039). Among 17 HER2-positive patients, 5 received trastuzumsab treatment. These patients tended to exhibit a prolonged interval from initial diagnosis to BM (p=0.057; Table 2 ). 
DISCUSSION
Breast cancer is the second most common cause of brain metastases, and represents 14-20% of all such cases. 
It has recently been demonstrated that gene expression
profiling can be used to predict disease-free and overall survival in women with primary breast cancer, and several novel cancer subsets have previously been defined. (12) We divided the patients into two groups according to ER, PR, and HER2 expression. We observed that 24 patients The association with BRCA1 pathway dysfunction in TNBC patients raises the possibility that poly (ADP-ribose) polymerase (PARP) inhibitors may prove to have some efficacy. (19) One previous report asserted that ASD2281, a PARP inhibitor, exerted few adverse effects and evidenced activity in cancer associated with the BRCA1 or BRCA2 mutations.(20) Therefore, well-designed clinical trials with TN breast caner patients with BM using these agents will be necessary to improve clinical outcomes.
Our study has several limitations. First, in our analyses, we included only patients with complete information on ER, PR, and HER2 status available. This introduced some selection bias. Secondary, our small sample size probably contributed to limited power and imprecise effect estimates. Additionally, this was also a retrospective study, and lacked detailed molecular profiling and a hierarchical cluster analysis of the tissue. However, the results of this study do appear to support the proposition that patients with TNBC with BM have poorer outcomes than non-TN cases, and require novel treatments for the prevention or treatment of BM.
CONCLUSION
Patients with TNBC have a shorter time to development of brain metastases, and show shorter survival durations after a diagnosis of brain metastases, than do non-TNBC patients. Triple receptor status could be useful in predicting survival in breast cancer patients with brain metastasis. Further clinical trials are needed to prevent BM using novel agents in TNBC patients.
